<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL STATEMENTS OF BIOSHIELD TECHNOLOGIES, INC. FOR THE NINE MONTHS ENDED MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. </LEGEND> <PERIOD-TYPE> 9-MOS <FISCAL-YEAR-END> JUN-30-2000 <PERIOD-START> JUL-01-1999 <PERIOD-END> MAR-31-2000 <CASH> 5,015,138 <SECURITIES> 62,132 <RECEIVABLES> 364,083 <ALLOWANCES> 200,000 <INVENTORY> 230,571 <CURRENT-ASSETS> 5,894,919 <PP&E> 6,333,025 <DEPRECIATION> 453,874 <TOTAL-ASSETS> 12,402,719 <CURRENT-LIABILITIES> 3,924,657 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 4,000,000 <COMMON> 14,689,137 <OTHER-SE> (16,402,992) <TOTAL-LIABILITY-AND-EQUITY> 12,402,719 <SALES> 737,182 <TOTAL-REVENUES> 737,182 <CGS> 411,657 <TOTAL-COSTS> 411,657 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 0 <INCOME-PRETAX> (13,531,625) <INCOME-TAX> 0 <INCOME-CONTINUING> (13,288,792) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (13,314,160) <EPS-BASIC> (1.93) <EPS-DILUTED> 0<F1> <FN> <F1>DILUTED LOSS PER COMMON SHARE IS NOT DISCLOSED BECAUSE THE EFFECT OF THE EXCHANGE OR EXERCISE OF COMMON STOCK EQUIVALENTS WOULD BE ANTIDILUTIVE. </FN>